Inhibrx Biosciences (INBX) Income towards Parent Company (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Income towards Parent Company data on file, last reported at -$32.8 million in Q4 2025.

• Income towards Parent Company for Q4 2025 came in at -$32.8 million, up 31.4% year-over-year; the trailing twelve-month figure through Dec 2025 was -$140.1 million (down 108.3% YoY), and the FY2025 annual result was -$140.1 million, down 108.3% from the prior year.
• Income towards Parent Company improved to -$32.8 million in Q4 2025 per INBX's latest filing, from -$35.3 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $1.9 billion in Q2 2024 and troughed at -$92.0 million in Q4 2023.
• A 3-year average of $123.3 million and a median of -$43.9 million in 2024 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2024 and 2025: Income towards Parent Company soared 4048.85% in 2024, then plunged 101.54% in 2025.
• A 3-year view of Income towards Parent Company shows it stood at -$92.0 million in 2023, then surged by 47.96% to -$47.9 million in 2024, then soared by 31.4% to -$32.8 million in 2025.
• Business Quant data shows INBX's Income towards Parent Company at -$32.8 million in Q4 2025, -$35.3 million in Q3 2025, and -$28.7 million in Q2 2025.